Compare Supplements

INVESTIGATIONAL — no approved consumer dose. In trials, danuglipron was dosed orally twice daily WITH food and escalated weekly to target doses (e.g. up to 120-200 mg BID); a modified-release once-daily form was later under evaluation. Not for self-administration; only appropriate within a clinical trial.

Any time · with food

Oral tablet (investigational)

• Not an approved medicine — only appropriate within a clinical trial
• Hepatic-safety signal: a drug-induced liver-injury signal halted a once-daily formulation in development
• Expected: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — the GLP-1-class thyroid C-cell concern

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists